0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Blood Cancer Treatments Market Research Report 2026
Published Date: 2026-03-24
|
Report Code: QYRE-Auto-1E17751
Home | Market Reports | Health| Health Conditions| Cancer
Global Blood Cancer Treatments Market Research Report 2024
BUY CHAPTERS

Global Blood Cancer Treatments Market Research Report 2026

Code: QYRE-Auto-1E17751
Report
2026-03-24
Pages:142
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Blood Cancer Treatments Market

The global Blood Cancer Treatments market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Blood Cancer Treatments competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
The North American market for Blood Cancer Treatments is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Blood Cancer Treatments is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Blood Cancer Treatments include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Blood Cancer Treatments market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Blood Cancer Treatments. The Blood Cancer Treatments market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Blood Cancer Treatments market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Blood Cancer Treatments manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Blood Cancer Treatments Market Report

Report Metric Details
Report Name Blood Cancer Treatments Market
Segment by Type
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others
by Application
  • Leukemia
  • lymphoma
  • Myeloma
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Blood Cancer Treatments manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Blood Cancer Treatments sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Blood Cancer Treatments Market report?

Ans: The main players in the Blood Cancer Treatments Market are Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences

What are the Application segmentation covered in the Blood Cancer Treatments Market report?

Ans: The Applications covered in the Blood Cancer Treatments Market report are Leukemia, lymphoma, Myeloma, Others

What are the Type segmentation covered in the Blood Cancer Treatments Market report?

Ans: The Types covered in the Blood Cancer Treatments Market report are Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others

1 Blood Cancer Treatments Market Overview
1.1 Product Definition
1.2 Blood Cancer Treatments by Type
1.2.1 Global Blood Cancer Treatments Market Value by Type: 2025 vs 2032
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Blood Cancer Treatments by Application
1.3.1 Global Blood Cancer Treatments Market Value by Application: 2025 vs 2032
1.3.2 Leukemia
1.3.3 lymphoma
1.3.4 Myeloma
1.3.5 Others
1.4 Global Blood Cancer Treatments Market Size Estimates and Forecasts
1.4.1 Global Blood Cancer Treatments Revenue 2021–2032
1.4.2 Global Blood Cancer Treatments Sales 2021–2032
1.4.3 Global Blood Cancer Treatments Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Blood Cancer Treatments Market Competition by Manufacturers
2.1 Global Blood Cancer Treatments Sales Market Share by Manufacturers (2021–2026)
2.2 Global Blood Cancer Treatments Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Blood Cancer Treatments Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Blood Cancer Treatments, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Blood Cancer Treatments, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Blood Cancer Treatments, Product Types and Applications
2.7 Global Key Manufacturers of Blood Cancer Treatments, Date of Entry into the Industry
2.8 Global Blood Cancer Treatments Market Competitive Situation and Trends
2.8.1 Global Blood Cancer Treatments Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Blood Cancer Treatments Players Market Share by Revenue
2.8.3 Global Blood Cancer Treatments Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Blood Cancer Treatments Market Scenario by Region
3.1 Global Blood Cancer Treatments Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Blood Cancer Treatments Sales by Region: 2021–2032
3.2.1 Global Blood Cancer Treatments Sales by Region: 2021–2026
3.2.2 Global Blood Cancer Treatments Sales by Region: 2027–2032
3.3 Global Blood Cancer Treatments Revenue by Region: 2021–2032
3.3.1 Global Blood Cancer Treatments Revenue by Region: 2021–2026
3.3.2 Global Blood Cancer Treatments Revenue by Region: 2027–2032
3.4 North America Blood Cancer Treatments Market Facts & Figures by Country
3.4.1 North America Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Blood Cancer Treatments Sales by Country (2021–2032)
3.4.3 North America Blood Cancer Treatments Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Blood Cancer Treatments Market Facts & Figures by Country
3.5.1 Europe Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Blood Cancer Treatments Sales by Country (2021–2032)
3.5.3 Europe Blood Cancer Treatments Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Blood Cancer Treatments Market Facts & Figures by Region
3.6.1 Asia Pacific Blood Cancer Treatments Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Blood Cancer Treatments Sales by Region (2021–2032)
3.6.3 Asia Pacific Blood Cancer Treatments Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Blood Cancer Treatments Market Facts & Figures by Country
3.7.1 Latin America Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Blood Cancer Treatments Sales by Country (2021–2032)
3.7.3 Latin America Blood Cancer Treatments Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Blood Cancer Treatments Market Facts & Figures by Country
3.8.1 Middle East and Africa Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Blood Cancer Treatments Sales by Country (2021–2032)
3.8.3 Middle East and Africa Blood Cancer Treatments Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Blood Cancer Treatments Sales by Type (2021–2032)
4.1.1 Global Blood Cancer Treatments Sales by Type (2021–2026)
4.1.2 Global Blood Cancer Treatments Sales by Type (2027–2032)
4.1.3 Global Blood Cancer Treatments Sales Market Share by Type (2021–2032)
4.2 Global Blood Cancer Treatments Revenue by Type (2021–2032)
4.2.1 Global Blood Cancer Treatments Revenue by Type (2021–2026)
4.2.2 Global Blood Cancer Treatments Revenue by Type (2027–2032)
4.2.3 Global Blood Cancer Treatments Revenue Market Share by Type (2021–2032)
4.3 Global Blood Cancer Treatments Price by Type (2021–2032)
5 Segment by Application
5.1 Global Blood Cancer Treatments Sales by Application (2021–2032)
5.1.1 Global Blood Cancer Treatments Sales by Application (2021–2026)
5.1.2 Global Blood Cancer Treatments Sales by Application (2027–2032)
5.1.3 Global Blood Cancer Treatments Sales Market Share by Application (2021–2032)
5.2 Global Blood Cancer Treatments Revenue by Application (2021–2032)
5.2.1 Global Blood Cancer Treatments Revenue by Application (2021–2026)
5.2.2 Global Blood Cancer Treatments Revenue by Application (2027–2032)
5.2.3 Global Blood Cancer Treatments Revenue Market Share by Application (2021–2032)
5.3 Global Blood Cancer Treatments Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Blood Cancer Treatments Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Celgene
6.2.1 Celgene Company Information
6.2.2 Celgene Description and Business Overview
6.2.3 Celgene Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Celgene Blood Cancer Treatments Product Portfolio
6.2.5 Celgene Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Novartis Blood Cancer Treatments Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Company Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Bristol-Myers Squibb Blood Cancer Treatments Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Johnson & Johnson Blood Cancer Treatments Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Merck & Co.
6.6.1 Merck & Co. Company Information
6.6.2 Merck & Co. Description and Business Overview
6.6.3 Merck & Co. Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Merck & Co. Blood Cancer Treatments Product Portfolio
6.6.5 Merck & Co. Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AstraZeneca Blood Cancer Treatments Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Pfizer Blood Cancer Treatments Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Amgen
6.9.1 Amgen Company Information
6.9.2 Amgen Description and Business Overview
6.9.3 Amgen Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Amgen Blood Cancer Treatments Product Portfolio
6.9.5 Amgen Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Company Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Eli Lilly Blood Cancer Treatments Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 AbbVie
6.11.1 AbbVie Company Information
6.11.2 AbbVie Description and Business Overview
6.11.3 AbbVie Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 AbbVie Blood Cancer Treatments Product Portfolio
6.11.5 AbbVie Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Company Information
6.12.2 Takeda Description and Business Overview
6.12.3 Takeda Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Takeda Blood Cancer Treatments Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 Astellas
6.13.1 Astellas Company Information
6.13.2 Astellas Description and Business Overview
6.13.3 Astellas Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Astellas Blood Cancer Treatments Product Portfolio
6.13.5 Astellas Recent Developments/Updates
6.14 Ipsen
6.14.1 Ipsen Company Information
6.14.2 Ipsen Description and Business Overview
6.14.3 Ipsen Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Ipsen Blood Cancer Treatments Product Portfolio
6.14.5 Ipsen Recent Developments/Updates
6.15 Sanofi
6.15.1 Sanofi Company Information
6.15.2 Sanofi Description and Business Overview
6.15.3 Sanofi Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Sanofi Blood Cancer Treatments Product Portfolio
6.15.5 Sanofi Recent Developments/Updates
6.16 Bayer
6.16.1 Bayer Company Information
6.16.2 Bayer Description and Business Overview
6.16.3 Bayer Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Bayer Blood Cancer Treatments Product Portfolio
6.16.5 Bayer Recent Developments/Updates
6.17 Biogen Idec
6.17.1 Biogen Idec Company Information
6.17.2 Biogen Idec Description and Business Overview
6.17.3 Biogen Idec Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Biogen Idec Blood Cancer Treatments Product Portfolio
6.17.5 Biogen Idec Recent Developments/Updates
6.18 Teva
6.18.1 Teva Company Information
6.18.2 Teva Description and Business Overview
6.18.3 Teva Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Teva Blood Cancer Treatments Product Portfolio
6.18.5 Teva Recent Developments/Updates
6.19 Otsuka
6.19.1 Otsuka Company Information
6.19.2 Otsuka Description and Business Overview
6.19.3 Otsuka Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Otsuka Blood Cancer Treatments Product Portfolio
6.19.5 Otsuka Recent Developments/Updates
6.20 Eisai
6.20.1 Eisai Company Information
6.20.2 Eisai Description and Business Overview
6.20.3 Eisai Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Eisai Blood Cancer Treatments Product Portfolio
6.20.5 Eisai Recent Developments/Updates
6.21 Merck KGaA
6.21.1 Merck KGaA Company Information
6.21.2 Merck KGaA Description and Business Overview
6.21.3 Merck KGaA Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Merck KGaA Blood Cancer Treatments Product Portfolio
6.21.5 Merck KGaA Recent Developments/Updates
6.22 Gilead Sciences
6.22.1 Gilead Sciences Company Information
6.22.2 Gilead Sciences Description and Business Overview
6.22.3 Gilead Sciences Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 Gilead Sciences Blood Cancer Treatments Product Portfolio
6.22.5 Gilead Sciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Blood Cancer Treatments Industry Chain Analysis
7.2 Blood Cancer Treatments Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Blood Cancer Treatments Production Mode & Process Analysis
7.4 Blood Cancer Treatments Sales and Marketing
7.4.1 Blood Cancer Treatments Sales Channels
7.4.2 Blood Cancer Treatments Distributors
7.5 Blood Cancer Treatments Customer Analysis
8 Blood Cancer Treatments Market Dynamics
8.1 Blood Cancer Treatments Industry Trends
8.2 Blood Cancer Treatments Market Drivers
8.3 Blood Cancer Treatments Market Challenges
8.4 Blood Cancer Treatments Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Blood Cancer Treatments Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Blood Cancer Treatments Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Blood Cancer Treatments Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Blood Cancer Treatments Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Blood Cancer Treatments Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Blood Cancer Treatments Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Blood Cancer Treatments Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Blood Cancer Treatments Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Blood Cancer Treatments, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Blood Cancer Treatments, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Blood Cancer Treatments, Product Types and Applications
 Table 12. Global Key Manufacturers of Blood Cancer Treatments, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Blood Cancer Treatments Companies by Tier (Tier 1, Tier 2, Tier 3), based on Blood Cancer Treatments Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Blood Cancer Treatments Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Blood Cancer Treatments Sales by Region (K Units), 2021–2026
 Table 18. Global Blood Cancer Treatments Sales Market Share by Region (2021–2026)
 Table 19. Global Blood Cancer Treatments Sales by Region (K Units), 2027–2032
 Table 20. Global Blood Cancer Treatments Sales Market Share by Region (2027–2032)
 Table 21. Global Blood Cancer Treatments Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Blood Cancer Treatments Revenue Market Share by Region (2021–2026)
 Table 23. Global Blood Cancer Treatments Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Blood Cancer Treatments Revenue Market Share by Region (2027–2032)
 Table 25. North America Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Blood Cancer Treatments Sales by Country (K Units), 2021–2026
 Table 27. North America Blood Cancer Treatments Sales by Country (K Units), 2027–2032
 Table 28. North America Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Blood Cancer Treatments Sales by Country (K Units), 2021–2026
 Table 32. Europe Blood Cancer Treatments Sales by Country (K Units), 2027–2032
 Table 33. Europe Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Blood Cancer Treatments Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Blood Cancer Treatments Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Blood Cancer Treatments Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Blood Cancer Treatments Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Blood Cancer Treatments Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Blood Cancer Treatments Sales by Country (K Units), 2021–2026
 Table 42. Latin America Blood Cancer Treatments Sales by Country (K Units), 2027–2032
 Table 43. Latin America Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Blood Cancer Treatments Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Blood Cancer Treatments Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Blood Cancer Treatments Sales (K Units) by Type (2021–2026)
 Table 51. Global Blood Cancer Treatments Sales (K Units) by Type (2027–2032)
 Table 52. Global Blood Cancer Treatments Sales Market Share by Type (2021–2026)
 Table 53. Global Blood Cancer Treatments Sales Market Share by Type (2027–2032)
 Table 54. Global Blood Cancer Treatments Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Blood Cancer Treatments Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Blood Cancer Treatments Revenue Market Share by Type (2021–2026)
 Table 57. Global Blood Cancer Treatments Revenue Market Share by Type (2027–2032)
 Table 58. Global Blood Cancer Treatments Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Blood Cancer Treatments Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Blood Cancer Treatments Sales (K Units) by Application (2021–2026)
 Table 61. Global Blood Cancer Treatments Sales (K Units) by Application (2027–2032)
 Table 62. Global Blood Cancer Treatments Sales Market Share by Application (2021–2026)
 Table 63. Global Blood Cancer Treatments Sales Market Share by Application (2027–2032)
 Table 64. Global Blood Cancer Treatments Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Blood Cancer Treatments Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Blood Cancer Treatments Revenue Market Share by Application (2021–2026)
 Table 67. Global Blood Cancer Treatments Revenue Market Share by Application (2027–2032)
 Table 68. Global Blood Cancer Treatments Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Blood Cancer Treatments Price (US$/Unit) by Application (2027–2032)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Roche Blood Cancer Treatments Product
 Table 74. Roche Recent Developments/Updates
 Table 75. Celgene Company Information
 Table 76. Celgene Description and Business Overview
 Table 77. Celgene Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Celgene Blood Cancer Treatments Product
 Table 79. Celgene Recent Developments/Updates
 Table 80. Novartis Company Information
 Table 81. Novartis Description and Business Overview
 Table 82. Novartis Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Novartis Blood Cancer Treatments Product
 Table 84. Novartis Recent Developments/Updates
 Table 85. Bristol-Myers Squibb Company Information
 Table 86. Bristol-Myers Squibb Description and Business Overview
 Table 87. Bristol-Myers Squibb Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Bristol-Myers Squibb Blood Cancer Treatments Product
 Table 89. Bristol-Myers Squibb Recent Developments/Updates
 Table 90. Johnson & Johnson Company Information
 Table 91. Johnson & Johnson Description and Business Overview
 Table 92. Johnson & Johnson Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Johnson & Johnson Blood Cancer Treatments Product
 Table 94. Johnson & Johnson Recent Developments/Updates
 Table 95. Merck & Co. Company Information
 Table 96. Merck & Co. Description and Business Overview
 Table 97. Merck & Co. Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Merck & Co. Blood Cancer Treatments Product
 Table 99. Merck & Co. Recent Developments/Updates
 Table 100. AstraZeneca Company Information
 Table 101. AstraZeneca Description and Business Overview
 Table 102. AstraZeneca Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. AstraZeneca Blood Cancer Treatments Product
 Table 104. AstraZeneca Recent Developments/Updates
 Table 105. Pfizer Company Information
 Table 106. Pfizer Description and Business Overview
 Table 107. Pfizer Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Pfizer Blood Cancer Treatments Product
 Table 109. Pfizer Recent Developments/Updates
 Table 110. Amgen Company Information
 Table 111. Amgen Description and Business Overview
 Table 112. Amgen Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Amgen Blood Cancer Treatments Product
 Table 114. Amgen Recent Developments/Updates
 Table 115. Eli Lilly Company Information
 Table 116. Eli Lilly Description and Business Overview
 Table 117. Eli Lilly Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Eli Lilly Blood Cancer Treatments Product
 Table 119. Eli Lilly Recent Developments/Updates
 Table 120. AbbVie Company Information
 Table 121. AbbVie Description and Business Overview
 Table 122. AbbVie Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. AbbVie Blood Cancer Treatments Product
 Table 124. AbbVie Recent Developments/Updates
 Table 125. Takeda Company Information
 Table 126. Takeda Description and Business Overview
 Table 127. Takeda Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. Takeda Blood Cancer Treatments Product
 Table 129. Takeda Recent Developments/Updates
 Table 130. Astellas Company Information
 Table 131. Astellas Description and Business Overview
 Table 132. Astellas Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 133. Astellas Blood Cancer Treatments Product
 Table 134. Astellas Recent Developments/Updates
 Table 135. Ipsen Company Information
 Table 136. Ipsen Description and Business Overview
 Table 137. Ipsen Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 138. Ipsen Blood Cancer Treatments Product
 Table 139. Ipsen Recent Developments/Updates
 Table 140. Sanofi Company Information
 Table 141. Sanofi Description and Business Overview
 Table 142. Sanofi Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 143. Sanofi Blood Cancer Treatments Product
 Table 144. Sanofi Recent Developments/Updates
 Table 145. Bayer Company Information
 Table 146. Bayer Description and Business Overview
 Table 147. Bayer Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 148. Bayer Blood Cancer Treatments Product
 Table 149. Bayer Recent Developments/Updates
 Table 150. Biogen Idec Company Information
 Table 151. Biogen Idec Description and Business Overview
 Table 152. Biogen Idec Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 153. Biogen Idec Blood Cancer Treatments Product
 Table 154. Biogen Idec Recent Developments/Updates
 Table 155. Teva Company Information
 Table 156. Teva Description and Business Overview
 Table 157. Teva Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 158. Teva Blood Cancer Treatments Product
 Table 159. Teva Recent Developments/Updates
 Table 160. Otsuka Company Information
 Table 161. Otsuka Description and Business Overview
 Table 162. Otsuka Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 163. Otsuka Blood Cancer Treatments Product
 Table 164. Otsuka Recent Developments/Updates
 Table 165. Eisai Company Information
 Table 166. Eisai Description and Business Overview
 Table 167. Eisai Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 168. Eisai Blood Cancer Treatments Product
 Table 169. Eisai Recent Developments/Updates
 Table 170. Merck KGaA Company Information
 Table 171. Merck KGaA Description and Business Overview
 Table 172. Merck KGaA Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 173. Merck KGaA Blood Cancer Treatments Product
 Table 174. Merck KGaA Recent Developments/Updates
 Table 175. Gilead Sciences Company Information
 Table 176. Gilead Sciences Description and Business Overview
 Table 177. Gilead Sciences Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 178. Gilead Sciences Blood Cancer Treatments Product
 Table 179. Gilead Sciences Recent Developments/Updates
 Table 180. Key Raw Materials Lists
 Table 181. Raw Materials Key Suppliers Lists
 Table 182. Blood Cancer Treatments Distributors List
 Table 183. Blood Cancer Treatments Customers List
 Table 184. Blood Cancer Treatments Market Trends
 Table 185. Blood Cancer Treatments Market Drivers
 Table 186. Blood Cancer Treatments Market Challenges
 Table 187. Blood Cancer Treatments Market Restraints
 Table 188. Research Programs/Design for This Report
 Table 189. Key Data Information from Secondary Sources
 Table 190. Key Data Information from Primary Sources
 Table 191. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Blood Cancer Treatments
 Figure 2. Global Blood Cancer Treatments Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Blood Cancer Treatments Market Share by Type: 2025 & 2032
 Figure 4. Chemotherapy Product Picture
 Figure 5. Targeted Therapy Product Picture
 Figure 6. Immunotherapy (Biologic Therapy) Product Picture
 Figure 7. Hormonal Therapy Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Blood Cancer Treatments Market Value by Application (US$ Million), 2021–2032
 Figure 10. Global Blood Cancer Treatments Market Share by Application: 2025 & 2032
 Figure 11. Leukemia
 Figure 12. lymphoma
 Figure 13. Myeloma
 Figure 14. Others
 Figure 15. Global Blood Cancer Treatments Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 16. Global Blood Cancer Treatments Market Size (US$ Million), 2021–2032
 Figure 17. Global Blood Cancer Treatments Sales (K Units), 2021–2032
 Figure 18. Global Blood Cancer Treatments Average Price (US$/Unit), 2021–2032
 Figure 19. Blood Cancer Treatments Report Years Considered
 Figure 20. Blood Cancer Treatments Sales Share by Manufacturers in 2025
 Figure 21. Global Blood Cancer Treatments Revenue Share by Manufacturers in 2025
 Figure 22. Top 5 and Top 10 Global Blood Cancer Treatments Players: Market Share by Revenue in Blood Cancer Treatments in 2025
 Figure 23. Blood Cancer Treatments Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 24. Global Blood Cancer Treatments Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 25. North America Blood Cancer Treatments Sales Market Share by Country (2021–2032)
 Figure 26. North America Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
 Figure 27. United States Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Canada Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Europe Blood Cancer Treatments Sales Market Share by Country (2021–2032)
 Figure 30. Europe Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
 Figure 31. Germany Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. France Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. U.K. Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Italy Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Russia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Asia Pacific Blood Cancer Treatments Sales Market Share by Region (2021–2032)
 Figure 37. Asia Pacific Blood Cancer Treatments Revenue Market Share by Region (2021–2032)
 Figure 38. China Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Japan Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. South Korea Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. India Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Australia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. China Taiwan Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Southeast Asia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Latin America Blood Cancer Treatments Sales Market Share by Country (2021–2032)
 Figure 46. Latin America Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
 Figure 47. Mexico Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Brazil Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Argentina Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Colombia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Middle East and Africa Blood Cancer Treatments Sales Market Share by Country (2021–2032)
 Figure 52. Middle East and Africa Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
 Figure 53. Turkey Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Saudi Arabia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. UAE Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. Global Sales Market Share of Blood Cancer Treatments by Type (2021–2032)
 Figure 57. Global Revenue Market Share of Blood Cancer Treatments by Type (2021–2032)
 Figure 58. Global Blood Cancer Treatments Price (US$/Unit) by Type (2021–2032)
 Figure 59. Global Sales Market Share of Blood Cancer Treatments by Application (2021–2032)
 Figure 60. Global Revenue Market Share of Blood Cancer Treatments by Application (2021–2032)
 Figure 61. Global Blood Cancer Treatments Price (US$/Unit) by Application (2021–2032)
 Figure 62. Blood Cancer Treatments Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS